Monday, 23 September 2019

Anaphore changes corporate name to RuiYi

05 October 2012 | News | By BioSpectrum Bureau

Anaphore changes corporate name to RuiYi

Anaphore is now RuiYi

Anaphore is now RuiYi

Singapore: Anaphore changed its corporate name to RuiYi. As part of the company's shift in strategy to the R&D of novel biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs), RuiYi has also added three seasoned leaders to its management team in Shanghai.

"RuiYi's new direction will enable us to focus on building our capabilities in Shanghai as we collaborate with a number of innovative drug discovery and development companies to advance our technology," commented Mr Paul Grayson, president and CEO, RuiYi.

RuiYi also announced today that it has added three key members to its management team to guide its GPCR drug discovery efforts, including Dr Chris Song, as director of operations; Dr Shouhua (Josh) Xiao, as senior director of protein technology; and Dr Lei Shi, as director of antibody discovery.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls